The Effects of Omalizumab (Anti-IgE) on the Late-phase Response to Nasal Allergen Challenge

NCT01003301 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

19

Enrollment

OTHER

Sponsor class

Conditions

Cat Allergy

Interventions

DRUG: Omalizumab
DRUG: Placebo

Sponsor

Johns Hopkins University

Collaborators

[object Object]
[object Object]